Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Breast Cancer Res Treat ; 135(2): 581-9, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22869285

ABSTRACT

Adjuvant chemotherapy significantly decreases recurrences and improves survival in women with early breast cancer (BC). However, the side effects of chemotherapy include weight gain, which is associated with poorer prognosis. We have previously demonstrated that by means of a comprehensive dietary modification which aims at lowering insulin levels it is possible to reduce body weight and decrease the bioavailability of insulin, sex hormones and the growth factors linked to BC risk and prognosis. We are now going to present a randomized controlled study of adjuvant diet in BC patients undergoing chemotherapy. The diet was designed to prevent weight gain during chemotherapy treatment. Women of any age, operated for invasive BC, scheduled for adjuvant chemotherapy and without evidence of distant metastases, were randomized into a dietary intervention group and a control group. The intervention implied changing their usual diet for the whole duration of chemotherapy, following cooking classes and having lunch or dinner at the study centre at least twice per week. 96 BC patients were included in the study. The women in the intervention group showed a significant reduction in their body weight (2.9 kg on average), compared with the controls. They also significantly reduced body fat mass, waist and hip circumferences, biceps, underscapular and suprailiac skinfolds, compared with the women in the control group. Our results support the hypothesis that dietary intervention during adjuvant chemotherapy for BC is feasible and may prevent weight gain.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/therapy , Overweight/diet therapy , Weight Gain/drug effects , Adult , Anthracyclines/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant/adverse effects , Cyclophosphamide/administration & dosage , Diet, Macrobiotic , Diet, Mediterranean , Female , Fluorouracil/administration & dosage , Humans , Methotrexate/administration & dosage , Middle Aged , Overweight/chemically induced , Overweight/prevention & control , Taxoids/administration & dosage , Treatment Outcome
2.
Breast Cancer Res Treat ; 119(3): 753-65, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19565333

ABSTRACT

So far, studies on dietary antioxidant intake, including beta-carotene, vitamin C and vitamin E, and breast cancer risk are inconclusive. Thus, we addressed this question in the European Prospective Investigation into Cancer and Nutrition. During a median follow-up time of 8.8 years, 7,502 primary invasive breast cancer cases were identified. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI). All analyses were run stratified by menopausal status at recruitment and, additionally, by smoking status, alcohol intake, use of exogenous hormones and use of dietary supplements. In the multivariate analyses, dietary intake of beta-carotene, vitamin C and E was not associated with breast cancer risk in premenopausal [highest vs. lowest quintile: HR, 1.04 (95% CI, 0.85-1.27), 1.12 (0.92-1.36) and 1.11 (0.84-1.46), respectively] and postmenopausal women [0.93 (0.82-1.04), 0.98 (0.87-1.11) and 0.92 (0.77-1.11), respectively]. However, in postmenopausal women using exogenous hormones, high intake of beta-carotene [highest vs. lowest quintile; HR 0.79 (95% CI, 0.66-0.96), P (trend) 0.06] and vitamin C [0.88 (0.72-1.07), P (trend) 0.05] was associated with reduced breast cancer risk. In addition, dietary beta-carotene was associated with a decreased risk in postmenopausal women with high alcohol intake. Overall, dietary intake of beta-carotene, vitamin C and E was not related to breast cancer risk in neither pre- nor postmenopausal women. However, in subgroups of postmenopausal women, a weak protective effect between beta-carotene and vitamin E from food and breast cancer risk cannot be excluded.


Subject(s)
Antioxidants/administration & dosage , Ascorbic Acid/administration & dosage , Breast Neoplasms/epidemiology , Diet , Vitamin E/administration & dosage , beta Carotene/administration & dosage , Adult , Aged , Europe , Female , Humans , Middle Aged , Postmenopause , Premenopause , Proportional Hazards Models , Risk , Surveys and Questionnaires
3.
Br J Cancer ; 100(11): 1817-23, 2009 Jun 02.
Article in English | MEDLINE | ID: mdl-19436304

ABSTRACT

We examined plasma concentrations of phyto-oestrogens in relation to risk for subsequent prostate cancer in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. Concentrations of isoflavones genistein, daidzein and equol, and that of lignans enterolactone and enterodiol, were measured in plasma samples for 950 prostate cancer cases and 1042 matched control participants. Relative risks (RRs) for prostate cancer in relation to plasma concentrations of these phyto-oestrogens were estimated by conditional logistic regression. Higher plasma concentrations of genistein were associated with lower risk of prostate cancer: RR among men in the highest vs the lowest fifth, 0.71 (95% confidence interval (CI) 0.53-0.96, P trend=0.03). After adjustment for potential confounders this RR was 0.74 (95% CI 0.54-1.00, P trend=0.05). No statistically significant associations were observed for circulating concentrations of daidzein, equol, enterolactone or enterodiol in relation to overall risk for prostate cancer. There was no evidence of heterogeneity in these results by age at blood collection or country of recruitment, nor by cancer stage or grade. These results suggest that higher concentrations of circulating genistein may reduce the risk of prostate cancer but do not support an association with plasma lignans.


Subject(s)
Diet , Phytoestrogens/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/epidemiology , Case-Control Studies , Europe , Genistein/blood , Humans , Male , Middle Aged , Risk Factors
4.
Int J Biol Markers ; 20(3): 169-76, 2005.
Article in English | MEDLINE | ID: mdl-16240844

ABSTRACT

High calorie and fat consumption and the production of free radicals are two major mechanistic pathways between diet and disease. In this study we evaluated the effect of a plant-based diet poor in animal fat and rich in (n-3) fatty acids on fatty acids of serum phospholipids and on the production of reactive oxygen metabolites (ROMs). One hundred and four healthy female postmenopausal volunteers were recruited and randomized to a dietary intervention or a control group. Dietary intervention included a program of food education and biweekly common meals for 18 weeks. When the intervention and control groups were compared, it was seen that dietary intervention resulted in a significant reduction of saturated fatty acids (-1.5%) and a significant increase in (n-3) fatty acids (+20.6%), in particular docosahexaenoic acid (+24.8%). We observed that arachidonic acid decreased (-7.7%), while (n-6) fatty acids did not, and the (n-3)/(n-6) polyunsaturated ratio increased significantly (+24.1%). As expected, ROMs decreased significantly in the intervention group (-6%). The results indicated that a plant-based diet can improve the serum fatty acid profile and decrease ROMs production. These results suggest that a plant-based diet may reduce the body's exposure to oxidative stress.


Subject(s)
Diet, Vegetarian , Dietary Fats, Unsaturated/administration & dosage , Dietary Fats/adverse effects , Fatty Acids/blood , Free Radicals/blood , Aged , Arachidonic Acid/blood , Female , Humans , Linoleic Acid/blood , Middle Aged , Phospholipids/blood , Postmenopause , alpha-Linolenic Acid/blood
5.
Eur J Med Res ; 8(3): 109-19, 2003 Mar 27.
Article in English | MEDLINE | ID: mdl-12730032

ABSTRACT

BACKGROUND: Mistletoe preparations are among the most widely used unconventional cancer therapies in Central Europe. Their clinical effectiveness, however, is controversial. OBJECTIVE: To investigate whether prospective controlled clinical trials provide evidence for efficacy of mistletoe therapy in cancer. DESIGN: Systematic review. MATERIAL AND METHODS: Search of 11 electronic databases, reference lists and expert consultations. Criteria based analysis was performed to assess methodological quality of the studies. RESULTS: Twenty-three studies were identified: 16 randomized, 2 quasi-randomized and 5 non-randomized. Cancer sites included breast, lung, stomach, colon, rectum, head and neck, kidney, bladder, melanoma, glioma, and genital. Among these studies, statistically significant positive outcomes were reported for survival (n = 8), tumor remission (n = 1), overall quality of life (QOL) (n = 3), and QOL in relation to side effects during cytoreductive therapy (n = 3). Further, positive trends were reported for survival (n = 8), disease-free-survival (n = 1), and tumor remission (n = 2). Several studies reported no effect on survival (n = 4), disease-free-survival (n = 1), recurrence (n = 2), remission (n = 3), and QOL (n = 1). One study showed a negative trend for disease-free-survival. However, methodological quality of the studies was sometimes far below the standard that is today regarded as optimal or necessary. In view of substantial heterogeneity of the studies and potential positive and negative biases, we considered effect size estimation by quantitative synthesis to be unreliable and decided on a non-quantitative synthesis and discussion. Mistletoe therapy was well tolerated, and no major side effects were noted. CONCLUSIONS: Among 23 identified studies evaluated for clinically relevant outcome measures, 12 studies showed one or more statistically significant, positive results, another 7 studies showed at least one positive trend, 3 showed no effect and 1 had a negative trend. All studies, however, suffered from methodological shortcomings to some degree, and many of the studies are not conclusive. As several reasonably well conducted studies indicate beneficial effects, further properly designed trials should be encouraged. Future controlled studies should take into account the methodological limitations and potential biases of these past mistletoe trials.


Subject(s)
Antineoplastic Agents/therapeutic use , Mistletoe , Neoplasms/drug therapy , Phytotherapy , Plant Preparations/therapeutic use , Controlled Clinical Trials as Topic , Humans
6.
Int J Epidemiol ; 22 Suppl 2: S127-33, 1993.
Article in English | MEDLINE | ID: mdl-8132386

ABSTRACT

The validity of retrospective assessment of occupational exposure greatly depends on the amount of detail in the available information, on the knowledge of the specific industrial process by the experts, and on the criteria adopted to define relevant exposure. These criteria are difficult to standardize and are rarely made explicit in published reports, which makes it difficult to interpret inconsistencies among different studies. In two ongoing case-control studies on kidney cancer and, respectively, malignant lymphomas, a detailed occupational history was obtained and supplemented by 19 additional questionnaires, specifically addressing industrial activities where the knowledge of job title alone would have been insufficient for reliable exposure assessment. One further questionnaire was used to collect details of task and environment for all the other activities. These data are used to establish probability, intensity and frequency of exposure to 30 substances known or suspected to be carcinogenic from previous studies. There are two basic steps in the exposure assessment procedure: firstly, general rules are defined for each job within each activity covered by specific questionnaires; secondly the judgement is modulated according to the detailed tasks, working conditions and environment. To illustrate the process and to facilitate comparison with other studies, examples are given for a few common exposures in the textile and metal industries--the two most frequent economic activities in the study area--namely exposure to mineral oils, formaldehyde, aromatic solvents, chlorinated solvents and other organic solvents.


Subject(s)
Formaldehyde , Metals , Mineral Oil , Occupational Exposure , Solvents , Textiles , Case-Control Studies , Epidemiologic Methods , Humans , Industry , Retrospective Studies , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL